Post on 13-Feb-2017
l|||||||||||||ll||l||||||||l|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| US 20030061096A1
(19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0061096 A1
Gallivan et al. (43) Pub. Date: Mar. 27, 2003
(54) sYsTEM AND METHOD FOR UsE FOR Publication Classi?cation LINKING PRIMARY MARKET RESEARCH DATA WITH SECONDARY RESEARCH DATA (51) Int. c1.7 ................................................... .. G06F 17/60
(52) us. Cl. ................................................. .. 705/14; 705/2 (76) Inventors: Gerald J. Gallivan, Naples, FL (US);
Timothy A. Margraf, Medford, NJ (US); Lorie M. Preston, NeWtoWn, PA (57) ABSTRACT (US); Gerhard K. Gallwitz, Haddon?eld, NJ (US)
A computerized system and method for conducting a survey COIIfISPOHdGHCfI AddreSSI of the promotional activities of sales representatives for CAESAR, RIVISE, BERNSTEIN, speci?c pharmaceuticals of the various pharmaceutical com COHEN & POKOTILOW, LTD- panies. A single panel of physicians is provided to collect 12TH FLOOR’ SEVEN PENN CENTER data regarding both (1) the promotional activities of the sales 1635 MARKET STREET representatives Whom they have encountered, and (2) the PHILADELPHIA, PA 19103-2212 (US) diagnosis and treatment of their patients. The data is pro
_ vided into a database for analysis to evaluate any cause and (21) Appl' NO" 10/142,028 effect relationship betWeen the promotional activities of the (22) Filed: May 9, 2002 sales representatives and the pharmaceuticals prescribed by
them to their patients. Primary market research studies can Related US, Application Data also be conducted by select appropriate physicians from the
panel to Whom a survey is to be administered and by (63) Continuation-in-part of application No. 09/947,034, analyzing their ansWers in the context of the data in the
?led on Sep. 5, 2001. database.
I
Internet Client Communication
3 Protocol (ICCP API)
26 / 28 30
E
_ 4O
\ Staging Transformation System 22 and Staging Transformation 4
System Metadata
U/ZII-N --_u>\ ‘
2‘ "a 22 . Other Transactlon Data Model
(Raw Data) <— negrence ata
46 i \ Warehouse Decislon Support
System (DSS) Table Generation
52 48 ¢ )0 Data Warehouse cDh;ri‘:‘i:\i/|:,::e/‘
SQL Server : V (Dimenslonyvarehouse) : > Cusmmlza‘ion Summanzed Data P
ararneters
ll
Riggs; Client Data F213;?! Extracts Tools
Patent Application Publication Mar. 27, 2003 Sheet 1 0f 43 US 2003/0061096 A1
by :‘t 22-1 ,
P Internet Client Communication El
- \‘ > 5 Protocol
(ICCP API)
26 / 28 30
2/2_N 20 D
l +
\ Staging Transformation System 22 and Staging Transformation <——
System Metadata
[g] 24-N ‘ 24 44 42
\ - Other / Transactlon Data Model (Raw Data) 4- Regarence
I ata
Hg. 1 l 46
\ Warehouse Decision Support System (DSS) Table Generation
52 48 $ 50
Data Warehouse cglg?xsrzgit SQL Server <—-> (Dtmenslon warehouse) <—> Customization
Summarized Data Parameters
Front End Cllent Data Access Extracts
Tools
54 ' \ 56 58
Patent Application Publication Mar. 27, 2003 Sheet 4 of 43 US 2003/0061096 A1
Fig. 4 I Pharmaceutical Representative Tracking Form 0 Fax form daily to 888-XXX-XXXX I
Pharmaceutical representatives requesting to see Dr. Date; please pm“ Clearly 0 Did the representative get beyond the front desk I waiting room? . which company provided lunch? ' Enter today‘s date to the right
- Fill in the square in the appropriate column. I Correct EH! Incorrect 1: :I l l a n u 1' 0 [Office Staff First, Last Name] Call at 800-XXX~XXXX with any questions. M M D D
1“ Rep 2"‘l Rep Lunch 1“ Rep 2"1 Rep Lunch Company Y“ No Yes N0 Provided Company Yes No Yes No Provided
Abbott U U U U U Organon U U U / U U Allen & Hanburys U U U U U Ortho-McNeil U U U U U
Alla U U U U U PDI U U U U U Astra U U U U U P?zer Labs U U U U U AstraZeneca U U U U U Pharmacia U U U U U Aventis U U U U U Pratt U U U U U Bayer U U U U U Proct & Gamble U U U U U Beecham Labs U U U U Purdue Frederick U U U U U Bristol-Myers Squibb U U U U U Reliant U U U U U Boehringer lng. U U U U U Roche U U U U U Burroughs Wellcm U U U U U Roerig U U U U U Centocor U U U U U Ross Labs U U U U U Cerenex U U U U U Sandoz U U U U U Dura U U U U U Sankyo U U U U U Elan U U U U U Sanofi U U U U U
Fforest 74> _m U U U U U Schering U U U U U
GlaxoSmithKline U U U U U Schwarz U U U U U HitchingS U U U U U Searle U U U iUiw U Hoechst M.R. El El [:1 ‘it El Samarium it? "13 t1 [1 U Janssen U U U U U SmithKline U U U U U Key Pharma U U U U U Solvay U U U U U Knoll Pharma U U U U U Takeda U U U U U
Lederle U U U U U TAP U U U U U Lifecycle U U U U U UCB Pharma U U U U U Lilly U U U U U Upjohn U U U U U McNeil U U U U U Wallace U U U U U
Merck U r U U U U Watson U U U U U
Monarch U U U U U V Whitehall Robins U U U i U
Novartis U U U U U Wyeth-Ayerst U U U U U Novo Nordisk U U U U U Zeneca U U U U U
U NO REPS VISITED Write in Company Names Below If Not Found Above:
U OFFICE CLOSED g g [1 5 U U DOCl" OR OUT OF OFFICE (All reps visiting D U U D U of?ce MUST be recorded) U U U U U
I I] l] E B 0 0 Z 7 B 7 l: I
Patent Application Publication Mar. 27, 2003 Sheet 5 0f 43 US 2003/0061096 A1
Sales Rep Visits
Meetings and Events
‘Product Detail 1 Product FILLEGRH? Discussion Type. M Compared To: 2(LHRITINE isual “iii 7 paper [I No trade-off between power & non El Nanirnpairlng while drlving [I Nansedating even at 2x recommen
‘Sales Rep Visit
" I3 Gen Prd Disc I] None afHbove Pmdu‘t Dem“ Message otation ail-Detail‘ T’ Of?ce [ Edit Message 1 [ Done )(ccmtel J The Sales Rep stated that Filieg‘ra was a
great praduci, but did not mention retommended dosage‘
Product: EFiLLEGRH-Di
Na Prd Discussed
ime Spent with Rep: 7 > NJ min
Detail I-HLLEGRFI Detail Z-FiLLEGFiFi-D Product Detail 3
Product Discussion
two way
‘ 'ZHOURF Compared To. ZN Visual ?ld: v paper [I] Slg. rellefat Just 45 min. compared
: [i Smooih dist pseudophedrine-entir _ @@f [1 Powerful decangeshon even at ira
I [I For patients i2yr
F | g . 6 E! Gen Prd Disc [II None of?bove Edit Message [ Done (ancei
Patent Application Publication Mar. 27, 2003 Sheet 6 0f 43 US 2003/0061096 A1
Meeting or EventUlZ) Meeting or Event (Z/Z) Meeting/Event Do i 800/01? Speaker: Dr. Smith Sponsor: TopicMonogemel-n hypertensiod Speaker Info: v Local specialist
I Topic Quality: v 6 attendee (ount: I0
I Location: v Restaurant I Lotution Quohty: v Very Good
13 (ME (reditsoffereld
Product. (i Noxure‘ v prod (speci?c Program Length: v 1-2 hours
@QED(@
Fig. 8 DHy Impact Network - Version: ‘2.0.0
Fih "Took... Holy , "
\?silDake: Age, Handel, Haas: Inswance: , Location~
[401 IESSENTIAL HYPEFITENSIIJN i] Diagnosis Type
I Q] Paiientvisis
F NewlyDiagnosed F Mnd piM?deiale [7 Die! [-7 Résl I'- Alternative I7 PievD' ->-- F Seven [7 Exercisé I'- Ulhe'r'
r Did Paiienl Request Dlug By Name?
may‘); F Drug Requested [comm _1_] i
nx1~viagnosis1 [5112 I ma] Product Name. Form/Shengh '
ILIPITDH _§] poms TABLET i] , I" R" ' Dispensed I20 Scl'ieduia' BID i Re?lls: '3
' U'i'engejn Diué fiéotinerii lY/Nl Change Type: ‘Switched to a new Medication ' I
Piocbol Switch: » I ' ’ ‘ Plevious Product you; lzocon 3]
Why Switched: lno! achleving dashed LDL and HDL levels in plasma
Patent Application Publication Mar. 27, 2003 Sheet 7 0f 43 US 2003/0061096 A1
and Proposal Development With Client I / ’ 202 I/ 204 200
Research Provider ~
sixeienmg I Query Transaction Data Criteria and —- > Model = Quota Setting I
Client |
44 214 I
/I Research Instrument Development I 210/ I Develop Research ‘ | Secondary Reseeirch Transaction Data
' Instrument ‘ (e.g., Internet, Pink Model
212/,.|/ ‘ | Sheets, etc.) I It It
218_,_I___,———# Conduct Pretest |
: I Existing Research 216 Modify | <e-g-- @9351;
I Research response 8 , .)
Instrument \ 222 l v |\ Prepare 4I T 220
Survey I | Selected Network /228 _ _ — — w A ' — — — —' _' Physicians
Field Survey <__—J —> (e.g., On-line, telephone, mail, in person, \—
etc.)
224 226
r
. Query Transaction Data ‘ Analysls Of Survey Resullts Model ‘
I /23o Integrated Analysis
I / /232 l _ _ _ _ — — — — — — — _ —" “ —/— w I
Output Report(s) I
Client Perceptual Map Other Oualitative/ Report(s) Quantitative Report(s)
Patent Application Publication Mar. 27, 2003 Sheet 9 0f 43 US 2003/0061096 A1
<: .3 \bmbwbk $2536 922 12:23.65“ iotgnmwm 25 251515
Patent Application Publication Mar. 27, 2003 Sheet 11 0f 43 US 2003/0061096 A1
AS2603
6:0 0: 8.32:8 258:8 2: MQSQEQ: 1 200m 2225 32%3 2: m2: :mcEo: 2 :2: 222:8 2: o: 6320 65:05 2: coEmom 8 :03 EB ??woa @552: 2: £25258 :22/8 5:5 8860mm“ Emmi 2 8363 m b 28% Ec2w5€::-o>>: E RENEE:
$0522: 2522 2a 832:8 E0: @2282: 2: 65E E :82 8 220: $59
022582: $22223“: 2: 50: 3:2338
:2: E 38:86 53 m5 8 :5: d2: 2.: no 5:528: E 320 2m :2: 82603 6m?N 8260i 2:0 8 :2368 2558 5:223 :2: so 262: 2: :0 5:283“
2: 2:2: 2: dEnEE SN 9 2 65:9: @ :2: 51522: E M220 2: “32: 2: :O
33: “2:95.25 .wBBEE
:0 :3 m :5“ $00.50 5253 8:22am“ 2: so :38 92: E5322: 2: @238 2 3:32: 052::02 :EoEwomEoo m an 8 :22228 2 29228 moqwgommobou .32: $5382: 2: 28.6 o: :8: £3 wibmc< oucowucomwubonv
“$28328: 9.5222 b 32200522 >
0S .5
Patent Application Publication Mar. 27, 2003 Sheet 12 0f 43 US 2003/0061096 A1
mm~$>oo ho Eatuwnw umEmi. mEmoa 22:02.69
93k 2 in? 2:95 $5220... @000.
a: .5
EPZwEODE 395m, $2300 28 ummmcwz noon
03.3231 2 $5935? 2:025 .89 63 u zv 2352a 58 mmcsmm 2:254. E32 - 052225
Patent Application Publication Mar. 27, 2003 Sheet 17 0f 43 US 2003/0061096 A1
.33? “8:55
@3555 .E\ @595“ ??wmem @QEE 8 062 £2.35» MS“ \a 39% SN,“
.8553 35
H8 A? we 30 m hocnhm?m?q won m8 Q Hon Ho 5L (5 :6 b Ho 8 6.6% was m m8 m BBSHQ 6 @BE >2: $62?» no n33 wQEQEwQw 82> 256555
92605 32: H8 $528 85588
so 8mg :82? 2 80:33 How 2E? EVENE “233w Mo 8C3 38: 2t 5
22m “aims- b wcozhmohwn “2.62m b mmEuc: B 59555 >
E .5
US 2003/0061096 A1
o2": yam m?az HmHuc Hxom mat
xcm monk “o2 ....... .. mom morn 3am
amqs 19)].IBW
Patent Application Publication Mar. 27, 2003 Sheet 18 0f 43
NQEQEHMN .5.“ 53% a a E mmwcg?outu ~80
22m 3152 xmEoEgN b , . @ wwmcm>zowtm “moo > H
_J_\ r mmEuzE um=£m0 F